Jazz Pharmaceuticals' Ziihera Therapy Significantly Extends Survival in GEA Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Should l Buy JAZZ?
Source: PRnewswire
- Survival Breakthrough: In the global Phase 3 HERIZON-GEA-01 trial, patients receiving Ziihera in combination with chemotherapy achieved a median overall survival of 26.4 months, exceeding the control group by over seven months, marking a significant advancement in the treatment of HER2+ metastatic gastroesophageal adenocarcinoma.
- Progression-Free Survival Improvement: The median progression-free survival for Ziihera plus chemotherapy was 12.4 months, demonstrating significant efficacy compared to traditional treatments, which is expected to change clinical practice and enhance long-term survival rates for patients.
- Favorable Safety Profile: The safety profile of Ziihera was consistent with known HER2-targeted therapies, with no new safety signals identified, and a treatment-related adverse event rate of 71.8%, indicating the feasibility of this therapy in first-line treatment settings.
- Future Outlook: Jazz Pharmaceuticals plans to present these results at the ASCO GI meeting on January 8, 2026, which is expected to accelerate the FDA submission process and further solidify Ziihera's position as the new standard of care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JAZZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JAZZ
Wall Street analysts forecast JAZZ stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 166.290
Low
188.00
Averages
218.92
High
263.00
Current: 166.290
Low
188.00
Averages
218.92
High
263.00
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jazz Pharmaceuticals to Report Q4 and Full Year 2025 Results
- Earnings Announcement: Jazz Pharmaceuticals will report its Q4 and full year 2025 financial results on February 24, 2026, after U.S. market close, which is expected to significantly impact investor sentiment.
- Webcast Timing: Company management will host a webcast at 4:30 p.m. ET (9:30 p.m. GMT) to discuss the financial results and provide business updates, enhancing transparency for stakeholders.
- Registration Recommendation: Participants are advised to register at least 15 minutes prior to the webcast to ensure timely connection, reflecting the company's commitment to investor communication.
- Replay Availability: A replay of the webcast will be accessible via the Jazz Pharmaceuticals investor website, facilitating information access for investors who cannot attend live, thereby improving information dissemination.
See More
Harmony Biosciences: Financial Success Amidst Challenges
- Significant Sales Growth: Harmony Biosciences' Wakix has shown remarkable success since FDA approval in 2019, generating $160 million in revenue in 2020, with projections nearing $870 million by 2025, reflecting an average annual growth rate of about 40%, which lays a solid foundation for future profitability.
- Profitability Improvement: Harmony became profitable in 2021, achieving a net income of $186 million over the past 12 months, with a market capitalization of $2.1 billion and an earnings multiple of just 12, indicating strong performance in sales growth and margin expansion.
- Patent Protection Risks: Despite Wakix's success, it is expected to lose patent protection in 2030, potentially facing generic competition; however, Harmony is developing pitolisant variants to extend patent protection into the mid-2040s, demonstrating strategic foresight for future market positioning.
- Intensifying Market Competition: Harmony faces fierce competition from Jazz Pharmaceuticals, whose Xywav and Xyrem generated nearly $1.3 billion in revenue in the first nine months of 2025, and potential generic competition could impact Harmony's revenue, necessitating close monitoring of its market share dynamics.
See More
Harmony's Wakix Drug: Financial Success Amid Controversy
- Strong Financial Performance: Since FDA approval in 2019, Harmony's Wakix generated $160 million in revenue by 2020, with projected sales nearing $870 million by 2025, reflecting a 40% compound annual growth rate; however, the stock price has not followed suit, indicating market concerns about future prospects.
- Profitability Improvement: Harmony became profitable in 2021, achieving a net income of $186 million over the past 12 months, with a market cap of $2.1 billion and an earnings multiple of just 12, showcasing strong sales growth and margin expansion, yet market skepticism about sustainable growth remains.
- Patent Risk Concerns: Wakix is set to lose exclusive patent protection in 2030, prompting Harmony to develop new pitolisant variants to extend patent protection into the mid-2040s; however, market sentiment is cautious regarding the company's ability to fend off impending generic competition.
- Increased Competitive Pressure: Jazz Pharmaceuticals' Xywav and Xyrem generated nearly $1.3 billion in revenue in the first nine months of 2025, highlighting the intense competition Harmony faces, which could impact its market share and future revenue despite its strong financial performance.
See More
Zymeworks (ZYME) 2026 Milestones Expected to Drive Long-Term Value with Promising ZW191 Data
- ZW191 Clinical Progress: Zymeworks' ZW191 shows a 64% overall response rate in phase 1 trials for advanced solid tumors, particularly among gynecological cancer patients receiving doses of 6.4 mg/kg or higher, indicating significant therapeutic potential that could drive long-term value for the company.
- Dose Optimization Initiated: The company has commenced dose optimization of ZW191 in ovarian cancer in the previous quarter, aiming to enhance efficacy and meet patient needs, thereby strengthening its competitive position in the market.
- Zanidatamab Milestones: Zymeworks is poised to receive substantial milestone payments related to its licensed program Zanidatamab, which is approved in the U.S. for HER2-positive biliary tract cancer, showcasing the company's robust potential in the biopharmaceutical sector.
- Strong Cash Reserves: As of December 31, 2025, Zymeworks held approximately $270.6 million in cash, providing ample funding for future R&D and market expansion, thereby enhancing its capacity for sustained growth in the industry.
See More
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer to Drive Strategic Development
- Leadership Appointment: Jazz Pharmaceuticals appointed Thomas Riga as Chief Business Officer effective January 1, 2026, bringing over 25 years of pharmaceutical experience and a proven track record of leading over $2 billion in business development deals, which is expected to enhance the company's strategic growth initiatives.
- Successful Transaction Background: While serving as Chief Operating Officer at Chimerix, Riga successfully directed the sale of the company to Jazz, facilitating the approval and launch of the first therapy for H3K27M-mutant diffuse midline glioma, impacting approximately 2,000 children and young adults annually in the U.S., showcasing his exceptional ability to navigate complex regulatory environments.
- Strategic Vision: Riga expressed his intent to leverage the existing expertise and capabilities of the company to drive innovative strategic transactions, thereby strengthening Jazz's corporate development capabilities and creating shareholder value while addressing unmet medical needs.
- Company Mission: Jazz Pharmaceuticals is dedicated to developing potentially life-changing medicines, particularly in oncology and neuroscience, and Riga's appointment is expected to further bolster the company's research and marketing capabilities in these critical areas.
See More
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer to Drive Strategic Development
- Extensive Leadership Experience: Thomas Riga brings over 25 years of pharmaceutical industry experience, having successfully led over $2 billion in business development deals, which is expected to enhance Jazz's market competitiveness.
- Strategic Deal Maker: As Chief Operating Officer at Chimerix, Riga directed corporate strategy, successfully completing the acquisition and securing U.S. approval for a therapy targeting H3K27M-mutant brain tumors, impacting approximately 2,000 patients annually.
- Innovative Drug Development: Riga played a pivotal role in the launch of Modeyso™ (dordaviprone), the first treatment for an ultra-rare brain tumor affecting primarily children and young adults, demonstrating his commitment to addressing patient needs.
- Vision for Future Growth: Riga expressed his intent to leverage the company's existing expertise and capabilities to drive innovative strategic transactions aimed at enhancing shareholder value and making a meaningful impact for patients with unmet medical needs.
See More
Jazz Pharmaceuticals to Report Q4 and Full Year 2025 Results
- Earnings Announcement: Jazz Pharmaceuticals will report its Q4 and full year 2025 financial results on February 24, 2026, after U.S. market close, which is expected to significantly impact investor sentiment.
- Webcast Timing: Company management will host a webcast at 4:30 p.m. ET (9:30 p.m. GMT) to discuss the financial results and provide business updates, enhancing transparency for stakeholders.
- Registration Recommendation: Participants are advised to register at least 15 minutes prior to the webcast to ensure timely connection, reflecting the company's commitment to investor communication.
- Replay Availability: A replay of the webcast will be accessible via the Jazz Pharmaceuticals investor website, facilitating information access for investors who cannot attend live, thereby improving information dissemination.
See More
Harmony Biosciences: Financial Success Amidst Challenges
- Significant Sales Growth: Harmony Biosciences' Wakix has shown remarkable success since FDA approval in 2019, generating $160 million in revenue in 2020, with projections nearing $870 million by 2025, reflecting an average annual growth rate of about 40%, which lays a solid foundation for future profitability.
- Profitability Improvement: Harmony became profitable in 2021, achieving a net income of $186 million over the past 12 months, with a market capitalization of $2.1 billion and an earnings multiple of just 12, indicating strong performance in sales growth and margin expansion.
- Patent Protection Risks: Despite Wakix's success, it is expected to lose patent protection in 2030, potentially facing generic competition; however, Harmony is developing pitolisant variants to extend patent protection into the mid-2040s, demonstrating strategic foresight for future market positioning.
- Intensifying Market Competition: Harmony faces fierce competition from Jazz Pharmaceuticals, whose Xywav and Xyrem generated nearly $1.3 billion in revenue in the first nine months of 2025, and potential generic competition could impact Harmony's revenue, necessitating close monitoring of its market share dynamics.
See More
Harmony's Wakix Drug: Financial Success Amid Controversy
- Strong Financial Performance: Since FDA approval in 2019, Harmony's Wakix generated $160 million in revenue by 2020, with projected sales nearing $870 million by 2025, reflecting a 40% compound annual growth rate; however, the stock price has not followed suit, indicating market concerns about future prospects.
- Profitability Improvement: Harmony became profitable in 2021, achieving a net income of $186 million over the past 12 months, with a market cap of $2.1 billion and an earnings multiple of just 12, showcasing strong sales growth and margin expansion, yet market skepticism about sustainable growth remains.
- Patent Risk Concerns: Wakix is set to lose exclusive patent protection in 2030, prompting Harmony to develop new pitolisant variants to extend patent protection into the mid-2040s; however, market sentiment is cautious regarding the company's ability to fend off impending generic competition.
- Increased Competitive Pressure: Jazz Pharmaceuticals' Xywav and Xyrem generated nearly $1.3 billion in revenue in the first nine months of 2025, highlighting the intense competition Harmony faces, which could impact its market share and future revenue despite its strong financial performance.
See More
Zymeworks (ZYME) 2026 Milestones Expected to Drive Long-Term Value with Promising ZW191 Data
- ZW191 Clinical Progress: Zymeworks' ZW191 shows a 64% overall response rate in phase 1 trials for advanced solid tumors, particularly among gynecological cancer patients receiving doses of 6.4 mg/kg or higher, indicating significant therapeutic potential that could drive long-term value for the company.
- Dose Optimization Initiated: The company has commenced dose optimization of ZW191 in ovarian cancer in the previous quarter, aiming to enhance efficacy and meet patient needs, thereby strengthening its competitive position in the market.
- Zanidatamab Milestones: Zymeworks is poised to receive substantial milestone payments related to its licensed program Zanidatamab, which is approved in the U.S. for HER2-positive biliary tract cancer, showcasing the company's robust potential in the biopharmaceutical sector.
- Strong Cash Reserves: As of December 31, 2025, Zymeworks held approximately $270.6 million in cash, providing ample funding for future R&D and market expansion, thereby enhancing its capacity for sustained growth in the industry.
See More
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer to Drive Strategic Development
- Leadership Appointment: Jazz Pharmaceuticals appointed Thomas Riga as Chief Business Officer effective January 1, 2026, bringing over 25 years of pharmaceutical experience and a proven track record of leading over $2 billion in business development deals, which is expected to enhance the company's strategic growth initiatives.
- Successful Transaction Background: While serving as Chief Operating Officer at Chimerix, Riga successfully directed the sale of the company to Jazz, facilitating the approval and launch of the first therapy for H3K27M-mutant diffuse midline glioma, impacting approximately 2,000 children and young adults annually in the U.S., showcasing his exceptional ability to navigate complex regulatory environments.
- Strategic Vision: Riga expressed his intent to leverage the existing expertise and capabilities of the company to drive innovative strategic transactions, thereby strengthening Jazz's corporate development capabilities and creating shareholder value while addressing unmet medical needs.
- Company Mission: Jazz Pharmaceuticals is dedicated to developing potentially life-changing medicines, particularly in oncology and neuroscience, and Riga's appointment is expected to further bolster the company's research and marketing capabilities in these critical areas.
See More
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer to Drive Strategic Development
- Extensive Leadership Experience: Thomas Riga brings over 25 years of pharmaceutical industry experience, having successfully led over $2 billion in business development deals, which is expected to enhance Jazz's market competitiveness.
- Strategic Deal Maker: As Chief Operating Officer at Chimerix, Riga directed corporate strategy, successfully completing the acquisition and securing U.S. approval for a therapy targeting H3K27M-mutant brain tumors, impacting approximately 2,000 patients annually.
- Innovative Drug Development: Riga played a pivotal role in the launch of Modeyso™ (dordaviprone), the first treatment for an ultra-rare brain tumor affecting primarily children and young adults, demonstrating his commitment to addressing patient needs.
- Vision for Future Growth: Riga expressed his intent to leverage the company's existing expertise and capabilities to drive innovative strategic transactions aimed at enhancing shareholder value and making a meaningful impact for patients with unmet medical needs.
See More
